27594346|t|Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication
27594346|a|Hepatitis delta virus (HDV) in conjunction with hepatitis B virus (HBV) increases adult morbidity and mortality. A number of studies have performed cost-benefit analyses for HBV interventions, but they have ignored the impact of HDV on these outcomes. Using a mathematical model of HBV - HDV epidemiology, we compare health benefits and cost outcomes of four interventions: testing with HBV adult vaccination (diagnosis), diagnosis with antiviral treatment for HBV infections (mono - infections), diagnosis with antiviral treatment for HBV - HDV infections (dual - infections), and awareness programs. The relationship between optimal levels and outcomes of each of these interventions and HDV prevalence in HBV infected individuals ranging from 0 to 50% is determined. Over a 50 year period under no intervention, HBV prevalence, per capita total cost and death toll increase by 2.25%, -$11 and 2.6-fold respectively in moderate HDV endemic regions compared to mono - infected regions; the corresponding values for high HDV endemic regions are 4.2%, -$21 and 3.9-fold. Optimal interventions can be strategized similarly in mono and dually endemic regions. Only implementation of all four interventions achieves a very low HBV prevalence of around 1.5% in a moderate HDV endemic region such as China, with 2.8 million fewer deaths compared to no intervention. Although the policy of implementation of all four interventions costs additional $382 billion compared to no intervention, it still remains cost - effective with an incremental cost - effectiveness ratio of $1400/ QALY. Very high efficacy awareness programs achieve less prevalence with fewer deaths at a lower cost compared to treatment and/or vaccination programs. HDV substantially affects the performance of any HBV - related intervention. Its exclusion results in over-estimation of the effectiveness of HBV interventions.
27594346	26	51	endemic hepatitis D virus	T005	UMLS:C0011220
27594346	55	72	hepatitis B virus	T005	UMLS:C0019169
27594346	73	84	eradication	T058	UMLS:C3178994
27594346	85	106	Hepatitis delta virus	T005	UMLS:C0011220
27594346	108	111	HDV	T005	UMLS:C0011220
27594346	133	150	hepatitis B virus	T005	UMLS:C0019169
27594346	152	155	HBV	T005	UMLS:C0019169
27594346	210	217	studies	T062	UMLS:C2603343
27594346	259	262	HBV	T005	UMLS:C0019169
27594346	263	276	interventions	T058	UMLS:C0184661
27594346	314	317	HDV	T005	UMLS:C0011220
27594346	345	363	mathematical model	T170	UMLS:C0876936
27594346	367	370	HBV	T005	UMLS:C0019169
27594346	373	376	HDV	T005	UMLS:C0011220
27594346	444	457	interventions	T058	UMLS:C0184661
27594346	472	475	HBV	T005	UMLS:C0019169
27594346	482	493	vaccination	T058	UMLS:C0042196
27594346	495	504	diagnosis	T062	UMLS:C1704656
27594346	507	516	diagnosis	T062	UMLS:C1704656
27594346	522	541	antiviral treatment	T058	UMLS:C2363964
27594346	546	560	HBV infections	T038	UMLS:C0019163
27594346	569	579	infections	T038	UMLS:C3714514
27594346	582	591	diagnosis	T062	UMLS:C1704656
27594346	597	616	antiviral treatment	T058	UMLS:C2363964
27594346	621	624	HBV	T005	UMLS:C0019169
27594346	627	630	HDV	T005	UMLS:C0011220
27594346	631	641	infections	T038	UMLS:C3714514
27594346	650	660	infections	T038	UMLS:C3714514
27594346	757	770	interventions	T058	UMLS:C0184661
27594346	775	778	HDV	T005	UMLS:C0011220
27594346	793	796	HBV	T005	UMLS:C0019169
27594346	797	805	infected	T033	UMLS:C0439663
27594346	806	817	individuals	T098	UMLS:C0027361
27594346	883	898	no intervention	T033	UMLS:C0243095
27594346	900	903	HBV	T005	UMLS:C0019169
27594346	942	947	death	T033	UMLS:C1306577
27594346	1015	1018	HDV	T005	UMLS:C0011220
27594346	1054	1062	infected	T033	UMLS:C0439663
27594346	1106	1109	HDV	T005	UMLS:C0011220
27594346	1163	1176	interventions	T058	UMLS:C0184661
27594346	1274	1287	interventions	T058	UMLS:C0184661
27594346	1288	1296	achieves	T033	UMLS:C0432600
27594346	1308	1311	HBV	T005	UMLS:C0019169
27594346	1352	1355	HDV	T005	UMLS:C0011220
27594346	1379	1384	China	T082	UMLS:C0008115
27594346	1428	1443	no intervention	T033	UMLS:C0243095
27594346	1458	1464	policy	T170	UMLS:C0242456
27594346	1495	1508	interventions	T058	UMLS:C0184661
27594346	1551	1566	no intervention	T033	UMLS:C0243095
27594346	1773	1782	treatment	T058	UMLS:C0087111
27594346	1790	1801	vaccination	T058	UMLS:C0042196
27594346	1812	1815	HDV	T005	UMLS:C0011220
27594346	1861	1864	HBV	T005	UMLS:C0019169
27594346	1875	1887	intervention	T058	UMLS:C0184661
27594346	1954	1957	HBV	T005	UMLS:C0019169
27594346	1958	1971	interventions	T058	UMLS:C0184661